Evidence Grade E — Very limited evidence. 0 published studies. 0 registered clinical trials.
Medically reviewed by a licensed medical professional
Matrixyl 3000 is not a single peptide but a combination of two cosmetic peptides in one product — one that stimulates collagen production and one that reduces skin inflammation. Developed as a successor to the original Matrixyl, it is widely used in anti-ageing skincare products. It has no pharmaceutical approval.
Matrixyl 3000 is also known by these brand and alternate names:
No published studies found on PubMed.
Matrixyl 3000 has no pharmaceutical authorisation. It is widely used as a cosmetic ingredient. Small studies report wrinkle reduction, with a head-to-head comparison against the original Matrixyl suggesting greater statistical significance on wrinkle endpoints.
As a two-component combination, Matrixyl 3000's evidence should be interpreted alongside the individual component entries: Palmitoyl Tripeptide-1 (#139) and Palmitoyl Tetrapeptide-7 (#140). It is a topical cosmetic ingredient.
Research suggests the two components work through complementary mechanisms: Pal-GHK stimulates collagen and extracellular matrix production (pro-repair), while Pal-GQPR suppresses inflammatory signalling (anti-inflammatory). The rationale for combining them is that both matrix degradation and chronic low-grade inflammation contribute to skin ageing.
Research suggests small studies (24-39 participants) show wrinkle reduction, with a comparison against the original Matrixyl suggesting improved results. The combination rationale — addressing both collagen loss and inflammation simultaneously — is biologically plausible. All published data originate from the manufacturer. No large independent trials exist. It is not possible to determine from the combination studies which component is responsible for the observed effects. It is a topical cosmetic ingredient.
PeptideTrace tracks 0 registered clinical trials for Matrixyl 3000 sourced from ClinicalTrials.gov.
No trials registered on ClinicalTrials.gov for this compound.
Matrixyl 3000 is not a single peptide but a proprietary combination of two palmitoylated peptides: Palmitoyl Tripeptide-1 (Pal-GHK, MW 578.79 Da, CAS 147732-56-7) and Palmitoyl Tetrapeptide-7 (Pal-GQPR, MW ~694.9 Da, CAS 221227-05-0). Developed by Sederma (Croda), Matrixyl 3000 represents a second-generation formulation designed to provide synergistic anti-aging effects through dual-mechanism activity combining collagen stimulation with anti-inflammatory protection.
Research suggests the two components operate through complementary mechanisms. Pal-GHK (Palmitoyl Tripeptide-1) is a matrikine that stimulates fibroblast collagen production through TGF-beta pathway signaling, with reported in vitro increases of collagen I (+258%), fibronectin (+164%), and hyaluronic acid (+179%). Pal-GQPR (Palmitoyl Tetrapeptide-7) is an immunoglobulin G fragment (positions 224-227) that suppresses IL-6 production by up to 40% at basal levels and 86% under UV-induced conditions, providing anti-inflammatory protection against UV-mediated collagen degradation.
A split-face study (N=24, 2 months) reported significant deep wrinkle reduction and reduced roughness (p<0.01). A head-to-head comparison versus the original Matrixyl (N=25) showed Matrixyl 3000 achieved p<0.01 significance versus p<0.05 for original Matrixyl on wrinkle endpoints. Manufacturer claims include 45% deep wrinkle reduction at 2 months and 68% at 6 months. In vitro, the combination produced greater effects than either component alone, supporting the synergy hypothesis.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
GHK has no pharmaceutical authorisation. Small cosmetic studies of the copper-complexed form (GHK-Cu) have reported improvements in skin appearance measures. No pharmaceutical clinical trials for injectable use have been completed. As with GHK-Cu (#85), the cosmetic evidence base for topical use should be distinguished from claims about injectable use. Gene expression profiling studies have reported broad effects, but observational genomic changes do not constitute evidence of therapeutic efficacy. This entry overlaps substantially with GHK-Cu (#85).
Argireline has no pharmaceutical authorisation. It is widely available as a cosmetic ingredient in over-the-counter skincare products. Small industry-sponsored studies have reported wrinkle depth reductions of 17–30% with topical application. The key scientific question is whether sufficient peptide penetrates intact skin to reach neuromuscular junctions and produce a meaningful effect. The molecule's size exceeds the conventional limit for transdermal absorption. Argireline's cosmetic use in formulated skincare products represents a fundamentally different risk profile from injectable use.
GHK-Cu has no pharmaceutical authorisation from any regulatory agency. It is widely available as a cosmetic ingredient in over-the-counter skincare products, where it is marketed for skin conditioning. A small study comparing GHK-Cu cream to vitamin C and retinoic acid creams reported improvements in skin appearance measures. No pharmaceutical clinical trials for injectable GHK-Cu have been completed. The compound's cosmetic use (topical, in formulated skincare products) should be clearly distinguished from its unregulated availability as an injectable research compound. These represent fundamentally different risk profiles.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
